BioSpace News Archive

Business

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2018 Ended December 31, 2017

Consolidated revenues for the third quarter were $2.5 million, an increase of $0.2 million or approximately 9% from the comparable period in the prior year.

February 12, 2018

·

4 min read

Biotech Bay

Adamas Announces New Employment Inducement Grant - Feb. 12, 2018

The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan.

February 12, 2018

·

1 min read

Business

Orthofix Schedules Fourth Quarter and Fiscal 2017 Earnings Release and Conference Call for February 26, 2018

Brad Mason, Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 4:30 p.m. ET the same day.

February 12, 2018

·

1 min read

Business

Foundation Fighting Blindness Will Provide Up to $7.5M in Funding to Develop Proqr’s Candidate QR-421a for Usher Syndrome Type 2A

Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.

February 12, 2018

·

7 min read

Voyager Therapeutics Announces New Data Presentati

Business

Booming Lakepharma to Create 100 New Jobs in Massachusetts Expansion

The company plans to add approximately 100 positions at the Center by 2020.

February 12, 2018

·

2 min read

Genetown

BioStem Technologies Inc. Announces New Transfer Agent, V Stock Transfer

Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy.

February 12, 2018

·

1 min read

Biotech Beach

Cytori Therapeutics Announces Inducement Grants for New Employees - Feb. 12, 2018

The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee’s employment commencement date with the Company.

February 12, 2018

·

1 min read

Policy

MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct a Clinical Trial With NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

MagForce anticipates to initiate patient enrollment in this study in the coming months.

February 12, 2018

·

1 min read

Business

Bovie Medical Corporation to Release Fourth Quarter and Fiscal Year 2017 Financial Results on March 12, 2018

Management will host a conference call at 4:30 p.m. Eastern Time on March 12 to discuss the results of the quarter and fiscal year and to host a question and answer session.

February 12, 2018

·

2 min read

Drug Development

Kadmon Announces Positive Topline Results from Phase II Study of KD025 in Idiopathic Pulmonary Fibrosis

Kadmon today announced topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib.

February 12, 2018

·

7 min read